Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M, Düngen HD, Corcea V, Donath F, Fuhr R, Gal P, Mikus G, Trenk D, Coenen M, Pires PV, Maschke C, Aliprantis AO, Besche N, Becker C. Böttcher M, et al. Among authors: gal p. Am J Cardiovasc Drugs. 2023 Mar;23(2):145-155. doi: 10.1007/s40256-022-00557-2. Epub 2023 Jan 12. Am J Cardiovasc Drugs. 2023. PMID: 36633816 Free PMC article. Clinical Trial.
Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly.
van Kraaij SJW, Borghans L, Klaassen ES, Gal P, van der Grond J, Tripp K, Winrow C, Glasser C, Groeneveld GJ. van Kraaij SJW, et al. Among authors: gal p. Br J Clin Pharmacol. 2023 Dec;89(12):3606-3617. doi: 10.1111/bcp.15861. Epub 2023 Aug 13. Br J Clin Pharmacol. 2023. PMID: 37488930 Clinical Trial.
First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator.
van Kraaij SJW, Gal P, Borghans LGJM, Klaassen ES, Dijkstra F, Winrow C, Glasser C, Groeneveld GJ. van Kraaij SJW, et al. Among authors: gal p. Clin Transl Sci. 2023 Aug;16(8):1381-1395. doi: 10.1111/cts.13537. Epub 2023 May 3. Clin Transl Sci. 2023. PMID: 37118895 Free PMC article. Clinical Trial.
Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial.
Heuberger JAAC, Rotmans JI, Gal P, Stuurman FE, van 't Westende J, Post TE, Daniels JMA, Moerland M, van Veldhoven PLJ, de Kam ML, Ram H, de Hon O, Posthuma JJ, Burggraaf J, Cohen AF. Heuberger JAAC, et al. Among authors: gal p. Lancet Haematol. 2017 Aug;4(8):e374-e386. doi: 10.1016/S2352-3026(17)30105-9. Epub 2017 Jun 29. Lancet Haematol. 2017. PMID: 28669689 Clinical Trial.
A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation.
Yfanti C, Vestbjerg B, Van't Westende J, Edvardsson N, Monfort LM, Olesen MS, Bentzen BH, Grunnet M, Eveleens Maarse BC, Diness JG, Kemme MJB, Sørensen U, Moerland M, van Esdonk MJ, Klaassen ES, Gal P, Holst AG. Yfanti C, et al. Among authors: gal p. Br J Clin Pharmacol. 2024 Apr;90(4):1027-1035. doi: 10.1111/bcp.15973. Epub 2024 Jan 8. Br J Clin Pharmacol. 2024. PMID: 37990600 Clinical Trial.
467 results